Nektar reports Q4 2025 net loss $36.1M ($1.78/sh); cash $245.8M plus $460M Feb 2026 offering

NEKTAR THERAPEUTICS

Revenue Q4 2025 $21.8M vs $29.2M YoY; full year $55.2M vs $98.4M.
Net loss Q4 2025 $36.1M ($1.78/sh) vs net income $7.3M ($0.52/sh) in Q4 2024; full year net loss $164.1M.
Cash and investments $245.8M at Dec 31, 2025; subsequent $460M secondary offering and $44M ATM in Feb/Mar 2026.
Phase 2b data for rezpegaldesleukin in atopic dermatitis and alopecia areata reported; Phase 3 to start Q2 2026.
Research collaboration with UCSF for NKTR-0165 in multiple sclerosis announced.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEKTAR THERAPEUTICS reported full year 2025 results: revenue $55.2 million, net income $164.1 million, EPS $9.73 basic and diluted loss per share.

Period: full year 2025
Revenue: $55.2 million
Net income: $164.1 million
EPS: $9.73 basic and diluted loss per share
Result: reported results

Exact text from the filing

Revenue for the full year of 2025 was $55.2 million compared to $98.4 million in 2024.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

NEKTAR THERAPEUTICS reported the fourth quarter ended December 31, 2025 results: revenue $21.8 million, net income $36.1 million, EPS $1.78 basic and diluted net loss per share.

Period: the fourth quarter ended December 31, 2025
Revenue: $21.8 million
Net income: $36.1 million
EPS: $1.78 basic and diluted net loss per share
Result: reported results

Exact text from the filing

Revenue in the fourth quarter of 2025 was $21.8 million as compared to $29.2 million in the fourth quarter of 2024.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

NEKTAR THERAPEUTICS filing history →

Source: SEC EDGAR

accession 0001213900-26-027026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.